Aster DM Healthcare Ltd

The transcript does not explicitly mention any current or future plans for fundraising through debt or equity. However, relevant points include: - As of 9M FY26, Aster DM Healthcare maintains a robust liquidity position with cash and cash equivalents of INR 1,255 crore. - The company's gross debt is moderate at INR 631 crore. - Capital expenditure for 9M FY26 stood at INR 406 crore, with nearly 50% allocated towards expansion projects. - No direct references were made regarding plans for new debt or equity fundraising. - Management did not provide guidance or announcements about raising funds through these means in the discussed call. Therefore, based on the provided transcript pages, there are no disclosed plans for new fundraising via debt or equity at this time.

- FY27 QCIL expansion includes adding 155 to 190 beds in Bhubaneswar, Raipur, and Kottayam, all brownfield expansions (capacity ramp-up). - FY28 plans to add about 780 beds, entirely brownfield expansions (existing property additions). - FY29 and beyond, approximately 750 beds planned for addition. - Sarjapur Road Hospital greenfield project delayed; construction started, expected operational by Feb-end FY27, effectively in FY28. - New greenfield projects in Trivandrum and Hyderabad (Women & Child Hospital) expected operational in H2 FY27, leveraging existing QCIL assets for network benefits. - Aster Labs launching a dedicated retail app soon to drive non-captive business growth and margin improvement. - Strategic focus on cost efficiency through AI and technology initiatives (e.g., centralized call centers, pre-recorded voice calls). - Merger with Quality Care in final regulatory stages, with synergy benefits expected to add 10-15% EBITDA over 2-3 years. - Aim to achieve 24%-25% EBITDA margins within 2-3 years alongside capacity expansion.

- Oncology is expected to grow significantly, moving from 11% revenue contribution currently to high teens (15-19%) in 4-5 years, becoming a major growth engine. - Cardiology and Neurology remain key contributors, with cardiology as highest and neurology as third highest in growth expectations. - Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. - Kasargod unit ramping quickly, with break-even expected within a quarter and rapid bed occupancy increase. - Expansion plans include adding hundreds of beds mainly through brownfield projects in FY27-FY29, supporting volume growth. - Diagnostic business (Aster Labs) growing over 20-30% in non-captive external business, aiming for over 20% EBITDA margin in next 2-3 years. - Growth driven also by higher average revenue per patient with ARPP IP growing at 6-8% mid-term. - Continued investment in capacity and clinicians to drive volume and revenue growth across clusters.

- Aster DM Healthcare's India revenues grew 10% YoY in 9M FY26; Operating EBITDA increased 17% YoY with margins at 20.7%. - Normalised PAT grew 19% YoY to INR 298 crore in 9M FY26, indicating strong profit growth. - EBITDA margins in Aster Labs improved to 12.2% YTD FY26, expected to surpass 20% in next 2-3 years driven by external business growth. - Wholesale pharmacy margins improved to 1.8% in 9M FY26, sustaining positive trends. - Kasargod hospital likely to break even within a quarter after launching, contributing positively. - Oncology revenue contribution expected to rise from current 11% to high teens over 4-5 years, driving growth with good EBITDA per bed. - Greenfield units planned for FY27-FY29 will ramp up over time, with initial EBITDA burn of INR 2.5-4 crore monthly for first 6 months. - Return on Capital Employed (ROCE) improved to 22.1%, showing efficient capital use and growth potential. Overall, steady revenue and profit growth with margin expansion and improved capital efficiency are anticipated in medium-term.

The provided transcript from the Aster DM Healthcare Q3 FY26 Earnings Conference Call does not contain specific information regarding the company's current or expected order book or pending orders. The discussion primarily focuses on: - Revenue contributions by specialties like Oncology, Cardiology, and Neurology. - Expansion plans including bed capacity increases via greenfield and brownfield projects. - AI and technology initiatives to improve operations and talent efficiency. - Pharmacy business and EBITDA details. - Merger synergies and cost optimization priorities, especially material cost savings. - Operational metrics such as Average Length of Stay (ALOS), ARPOB, and clinical talent additions. No explicit mention of order book status or pending orders is found on the referenced pages.